(Sharecast News) - French pharma giant Sanofi announced on Tuesday that it is to purchase London-based respiratory virus vaccine developer Vicebio for up to $1.6bn.
The deal, which adds an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to Sanofi's pipeline, is said to complement its...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE